CY2015011I1 - Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης - Google Patents

Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης

Info

Publication number
CY2015011I1
CY2015011I1 CY2015011C CY2015011C CY2015011I1 CY 2015011 I1 CY2015011 I1 CY 2015011I1 CY 2015011 C CY2015011 C CY 2015011C CY 2015011 C CY2015011 C CY 2015011C CY 2015011 I1 CY2015011 I1 CY 2015011I1
Authority
CY
Cyprus
Prior art keywords
microparticles containing
somatostatin analogues
containing somatostatin
analogues
microparticles
Prior art date
Application number
CY2015011C
Other languages
English (en)
Other versions
CY2015011I2 (el
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34593737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2015011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0326602A external-priority patent/GB0326602D0/en
Priority claimed from GB0406241A external-priority patent/GB0406241D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2015011I2 publication Critical patent/CY2015011I2/el
Publication of CY2015011I1 publication Critical patent/CY2015011I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
CY2015011C 2003-11-14 2015-03-26 Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης CY2015011I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0326602A GB0326602D0 (en) 2003-11-14 2003-11-14 Organic compounds
GB0406241A GB0406241D0 (en) 2004-03-19 2004-03-19 Organic compounds
PCT/EP2004/012870 WO2005046645A1 (en) 2003-11-14 2004-11-12 Microparticles comprising somatostatin analogues

Publications (2)

Publication Number Publication Date
CY2015011I2 CY2015011I2 (el) 2016-04-13
CY2015011I1 true CY2015011I1 (el) 2016-04-13

Family

ID=34593737

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100222T CY1110293T1 (el) 2003-11-14 2010-03-09 Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης
CY2015011C CY2015011I1 (el) 2003-11-14 2015-03-26 Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20101100222T CY1110293T1 (el) 2003-11-14 2010-03-09 Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης

Country Status (31)

Country Link
US (3) US7759308B2 (el)
EP (1) EP1686964B9 (el)
JP (1) JP4682145B2 (el)
KR (1) KR101233892B1 (el)
AR (1) AR047310A1 (el)
AT (1) ATE455537T1 (el)
AU (1) AU2004289055C1 (el)
BR (1) BRPI0416227B8 (el)
CA (1) CA2541944C (el)
CY (2) CY1110293T1 (el)
DE (1) DE602004025271D1 (el)
DK (1) DK1686964T3 (el)
EC (1) ECSP066565A (el)
ES (1) ES2339026T3 (el)
HK (1) HK1093682A1 (el)
HR (1) HRP20100190T1 (el)
IL (1) IL175286A (el)
IS (1) IS8480A (el)
LU (1) LU92701I2 (el)
MA (1) MA28155A1 (el)
MX (1) MXPA06005357A (el)
MY (1) MY158342A (el)
NO (2) NO337172B1 (el)
NZ (1) NZ546788A (el)
PE (1) PE20050581A1 (el)
PL (1) PL1686964T3 (el)
PT (1) PT1686964E (el)
RU (1) RU2404749C2 (el)
SI (1) SI1686964T1 (el)
TW (1) TWI295178B (el)
WO (1) WO2005046645A1 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
ES2755032T3 (es) * 2005-12-22 2020-04-21 Novartis Ag Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
AR066677A1 (es) * 2007-05-24 2009-09-02 Novartis Ag Formulacion de pasireotida. composicion farmaceutica para liberacion prolongada. microparticulas.
EP2247282B1 (en) * 2008-01-30 2014-08-20 Novartis AG Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
WO2009123903A1 (en) * 2008-04-03 2009-10-08 Zymogenetics, Inc. Hemostatic microspheres
JP5721624B2 (ja) 2008-07-08 2015-05-20 ノバルティス アーゲー 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit
US8822610B2 (en) 2008-12-22 2014-09-02 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US8815971B2 (en) 2008-12-22 2014-08-26 ATRP Solutions, Inc. Control over controlled radical polymerization processes
US9783628B2 (en) 2009-04-23 2017-10-10 ATRP Solutions, Inc. Dual-mechanism thickening agents for hydraulic fracturing fluids
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
WO2010123574A1 (en) 2009-04-23 2010-10-28 Atrp Solutions Inc Star macromolecules for personal and home care
US9587064B2 (en) 2010-12-08 2017-03-07 ATRP Solutions, Inc. Salt-tolerant star macromolecules
WO2013131879A1 (en) 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide
CN105189643B (zh) 2012-08-30 2019-01-15 派诺聚合物技术公司 用于水力压裂液的双重机制增稠剂
MX2015009938A (es) 2013-02-04 2015-10-05 Atrp Solutions Inc Macromoleculas en forma de estrella tolerantes a las sales.
CA2903769A1 (en) 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
TW201605488A (zh) * 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
CA2956431C (en) 2014-07-03 2023-01-31 ATRP Solutions, Inc. Surfactant-compatible star macromolecules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
WO1998032423A1 (en) * 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
ES2185373T3 (es) * 1998-07-23 2003-04-16 Sod Conseils Rech Applic Encapsulacion de peptidos solubles en agua.
WO2000004916A1 (en) * 1998-07-23 2000-02-03 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Encapsulation of water soluble peptides
NZ526127A (en) 1999-08-18 2005-02-25 Sod Conseils Rech Applic Use of a somatostatin analog in the manufacture of a medicament
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
JP4679822B2 (ja) * 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition

Also Published As

Publication number Publication date
TWI295178B (en) 2008-04-01
DE602004025271D1 (de) 2010-03-11
IL175286A0 (en) 2006-09-05
TW200529883A (en) 2005-09-16
NO337172B1 (no) 2016-02-01
EP1686964B1 (en) 2010-01-20
KR20060115873A (ko) 2006-11-10
MA28155A1 (fr) 2006-09-01
CA2541944C (en) 2014-02-25
LU92701I2 (fr) 2015-11-02
WO2005046645A1 (en) 2005-05-26
PE20050581A1 (es) 2005-09-09
RU2006120484A (ru) 2007-12-27
HK1093682A1 (en) 2007-03-09
DK1686964T3 (da) 2010-05-17
CY2015011I2 (el) 2016-04-13
US20100272809A1 (en) 2010-10-28
BRPI0416227B1 (pt) 2019-06-18
ECSP066565A (es) 2006-10-17
AR047310A1 (es) 2006-01-18
AU2004289055C1 (en) 2009-05-21
ATE455537T1 (de) 2010-02-15
NO2016003I1 (no) 2016-02-02
MY158342A (en) 2016-09-30
JP2007511482A (ja) 2007-05-10
IS8480A (is) 2006-05-23
US8188037B2 (en) 2012-05-29
RU2404749C2 (ru) 2010-11-27
EP1686964A1 (en) 2006-08-09
PL1686964T3 (pl) 2010-06-30
ES2339026T3 (es) 2010-05-14
MXPA06005357A (es) 2006-07-10
SI1686964T1 (sl) 2010-05-31
IL175286A (en) 2012-05-31
NZ546788A (en) 2009-12-24
NO20062777L (no) 2006-08-14
JP4682145B2 (ja) 2011-05-11
US7759308B2 (en) 2010-07-20
CY1110293T1 (el) 2015-01-14
AU2004289055A1 (en) 2005-05-26
HRP20100190T1 (hr) 2010-06-30
BRPI0416227A (pt) 2007-01-02
US20120214749A1 (en) 2012-08-23
CA2541944A1 (en) 2005-05-26
NO2016003I2 (no) 2016-02-02
KR101233892B1 (ko) 2013-02-18
AU2004289055B2 (en) 2008-10-30
PT1686964E (pt) 2010-02-04
BRPI0416227B8 (pt) 2021-05-25
EP1686964B9 (en) 2010-08-04
US20070212418A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
CY2015011I1 (el) Μικροσωματιδια που περιλαμβανουν αναλογα σωματοστατινης
NO20054669D0 (no) Substituerte kinobenzoxazinanaloger
DK1523493T3 (da) Nye tubulysinanaloge
DK1819670T3 (da) 12-Aryl-prostaglandinanaloger
DE60336538D1 (de) Stabilisiervorrichtung
ATE418924T1 (de) Marknagel
ATE336954T1 (de) Marknagel
DE60326590D1 (de) Tend lamotrigin
ATE462365T1 (de) Marknagel
DE10262037B4 (de) Achsmanschette
ATE375761T1 (de) Marknagel
DE60327130D1 (de) Entwicklungsgerät
DE60312100D1 (de) Kabelbaum
ITMI20022022A1 (it) Analoghi di nocicettina.
ITMI20020198A1 (it) (per)aloeteri
DK1648934T3 (da) Farmaceutisk sammensætning indeholdende cycliske somatostatinanaloger
ITMI20031144A0 (it) Analoghi del colchicoside
DE60314798D1 (de) Entwicklungsgerät
DE502004008312D1 (de) Magaziniervorrichtung
DE60330904D1 (de) Lisches bauteil
ATA8272002A (de) Lichtemittierendes bauelement
AT500592B8 (de) Entstörgerät
DE112004001195D2 (de) Traggeschirr
AT5889U3 (de) Brennholzspleisser
SE0200873D0 (sv) Microparticles